Bremelanotide Rx

Bremelanotide Rx / Comparisons

PT-141 vs Addyi: mechanism, dosing, and which one works faster

By the Bremelanotide Rx Editorial Team · 27 min read

Last updated 2026-07-24

TL;DR

PT-141 (bremelanotide) is an on-demand subcutaneous injection that activates melanocortin receptors centrally, typically within 45 minutes, and is used as needed. Addyi (flibanserin) is a daily oral pill that modulates serotonin and dopamine pathways, requiring 8 weeks of continuous use to show benefit. PT-141 caused nausea in 40% of trial participants and costs $150 to $300 per dose, while Addyi causes dizziness and hypotension and runs $60 to $100 monthly with insurance.

What is the main difference between PT-141 and Addyi?

PT-141 (bremelanotide) and Addyi (flibanserin) both have FDA approval for hypoactive sexual desire disorder in premenopausal women, but they work through completely different brain pathways and dosing schedules [1]. PT-141 is a melanocortin receptor agonist given by subcutaneous injection 45 minutes before anticipated sexual activity [2]. You inject 1.75 mg into the abdomen or thigh, and the drug activates MC3 and MC4 receptors in the hypothalamus and limbic system [3]. It's on-demand: you use it only when you want it, with a maximum of one dose per 24 hours and eight doses per month [1]. Addyi is a daily oral tablet (100 mg at bedtime) that you take continuously regardless of sexual activity [4]. It acts as a serotonin 5-HT1A receptor agonist and a 5-HT2A antagonist, and it also affects dopamine and norepinephrine signaling [5]. The registration trials showed meaningful benefit only after 8 weeks of daily use [4]. You don't stop and start it. The core difference: PT-141 is event-driven and central-acting via melanocortin, while Addyi is a daily neuropsychiatric medication that modulates monoamine tone over weeks. If you're looking for an acute response before an encounter, PT-141 is the only option. If you prefer a pill and are willing to wait two months, Addyi might fit better, but you'll be taking it every single night [1] [4]. For sourcing questions about PT-141 (including confusing marketplace listings and compounded versions), see best place to buy PT-141 and PT-141 peptide for sale Amazon.

How do PT-141 and Addyi work in the brain?

PT-141 binds to melanocortin-3 and melanocortin-4 receptors (MC3R and MC4R) in the hypothalamus, amygdala, and other limbic regions involved in motivation and reward [3]. These receptors are part of the melanocortin system, which evolved to regulate energy balance and feeding but also modulates sexual arousal [6]. Activation of MC4R in particular has been shown to enhance sexual motivation in animal models and in early human studies [7]. The drug does not work peripherally on genital blood flow. It's entirely central. That's why you can't compare it to sildenafil or other vasodilators used for erectile dysfunction [3] [6]. Addyi, on the other hand, is a multifunctional monoamine modulator. It's an agonist at 5-HT1A receptors, which disinhibits dopamine and norepinephrine release, and an antagonist at 5-HT2A receptors, which reduces serotonergic inhibition of sexual response [5] [8]. The hypothesis is that chronic dosing rebalances neurotransmitter tone in circuits that regulate desire. The mechanism is not fully understood, and the drug was originally developed as an antidepressant but failed in that indication [9]. Neither drug is a hormone. Neither replaces estrogen or testosterone. Both are meant to modify neural signaling related to sexual interest, not to correct a hormone deficiency [5] [10]. If you have documented low testosterone or are postmenopausal with vasomotor symptoms, hormone therapy is a separate conversation and is often needed first [10].

Which one works faster?

PT-141 works faster by a wide margin. In the phase 3 RECONNECT trials, women were instructed to inject PT-141 at least 45 minutes before anticipated sexual activity, and the drug showed a statistically significant increase in desire and reduction in distress within that treatment cycle [11]. The pharmacokinetics show peak plasma concentration around 1 hour post-injection, and the half-life is about 2.7 hours [1]. Addyi requires 8 weeks of daily dosing to reach the efficacy seen in the registration trials [4] [12]. In the registration studies, the co-primary endpoints (satisfying sexual events and sexual desire score) did not separate from placebo until week 8, and the effect size remained modest even then [12] [13]. You cannot take Addyi on-demand. If you skip doses, you lose any accumulated benefit [4]. So if the question is "can I take something an hour before sex," the answer is PT-141. If you want a daily regimen and are willing to wait two months to see if it helps, Addyi is the alternative [1] [4]. One important note: PT-141's fast onset does not mean it's a guaranteed or dramatic effect. The trial data show a mean increase of about 0.3 satisfying sexual events per month compared to placebo [11] [14]. Some women respond well, others not at all. But the response, if it happens, happens within hours, not weeks.

What are the side effects of PT-141 compared to Addyi?

PT-141's most common side effect is nausea, reported in 40% of women in the phase 3 trials [15]. Flushing occurred in 20%, headache in 11%, and injection-site reactions in 13% [15]. About 18% of participants discontinued the drug because of adverse events, most often due to nausea [15]. The nausea is typically mild to moderate, peaks within 2 hours, and resolves within 4 to 6 hours [15]. Taking an antiemetic like ondansetron before the injection reduces nausea significantly, and many clinicians now routinely co-prescribe it [15]. PT-141 also causes transient increases in blood pressure (mean systolic rise of 3 to 4 mm Hg) and a mild increase in heart rate [15]. The effect is small and short-lived, but the drug is contraindicated in uncontrolled hypertension or known cardiovascular disease [1] [15]. Addyi's signature side effect is dizziness, reported in 11% of trial participants, and somnolence (10%) [4] [12]. The drug carries a boxed warning for hypotension and syncope, especially if taken with alcohol [4] [16]. You are instructed not to drink alcohol at all while taking Addyi, because the combination can cause severe drops in blood pressure and fainting [4] [16]. Addyi is also contraindicated with moderate or strong CYP3A4 inhibitors (which includes grapefruit juice, many antifungals, and some antibiotics), because those drugs raise flibanserin levels and increase the risk of hypotension [4]. Other Addyi side effects: dry mouth (2%), nausea (10%), fatigue (9%), and insomnia (5%) [4] [12]. About 13% of women discontinued the drug in trials due to adverse events [12]. In practice, many providers find PT-141's side effect profile more manageable because nausea is predictable and short-term, and you can pretreat it. Addyi's hypotension risk and the absolute alcohol restriction are harder to work around, especially for women who drink socially [15] [16]. For a detailed look at PT-141 safety across all trials, see PT-141 in women.

How effective are PT-141 and Addyi in clinical trials?

Both drugs showed statistically significant but clinically modest improvements over placebo in their registration trials [11] [12]. PT-141: In the two phase 3 RECONNECT studies (1,267 women total), bremelanotide increased the mean number of satisfying sexual events by 0.5 to 0.6 per month compared to baseline, while placebo increased by 0.2 to 0.3 [11]. The drug-placebo difference was about 0.3 events per month [11] [14]. On the Female Sexual Function Index desire domain (range 1.2 to 6.0), PT-141 increased scores by 0.3 to 0.4 points more than placebo [11]. On distress (measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm), PT-141 reduced distress by about 5 points more than placebo on a 0-to-60 scale [11]. Those differences are statistically significant (p < 0.001), but the absolute magnitude is small [14] [17]. A re-analysis by independent researchers found that about 25% of PT-141 recipients reported "much improved" or "very much improved" desire, compared to 17% on placebo, a difference of 8 percentage points [14]. Addyi: In the three registration trials (over 2,400 women), flibanserin increased satisfying sexual events by 0.5 to 1.0 per month compared to baseline, while placebo increased by 0.3 to 0.4 [12] [18]. The drug-placebo difference was 0.4 to 0.5 events per month [12]. On the desire domain of the Female Sexual Function Index, Addyi improved scores by 0.3 to 0.4 points more than placebo [12]. Distress reduction was also modest, around 3 to 5 points better than placebo on the FSDS-R [12]. A critical re-analysis published in the Journal of Sex Research argued that both drugs' effect sizes are "small and of questionable clinical relevance," and that the FDA's approval was driven more by advocacy pressure than by solid evidence of benefit [17] [13]. The authors note that the mean change is less than half of one additional satisfying event per month, and that the subjective scales used (desire, distress) are prone to placebo effects [17] [13]. Both drugs work better in some women than others. In responder analyses, about 40% to 50% of PT-141 users had a clinically meaningful response (defined as at least a 30% increase in satisfying events and a 30% reduction in distress), compared to 30% on placebo [19]. For Addyi, similar responder rates were seen [12]. That means roughly one in five women benefits specifically because of the drug, not placebo.

Mean increase in satisfying sexual events per month vs placebo Phase 3 trial results, 12-24 weeks 0.3 PT-141 (bremela… 0.5 Addyi (flibanse… Source: Obstetrics and Gynecology 2019; Medical Letter on Drugs and Therapeutics 2019

Can you take PT-141 and Addyi together?

There are no published studies testing the combination of bremelanotide and flibanserin, and neither drug's label discusses co-administration [1] [4]. The two drugs act on different receptor systems (melanocortin vs serotonin/dopamine), so there's no obvious pharmacodynamic clash, but there's also no safety or efficacy data [1] [4] [5]. In practice, most clinicians would not prescribe them together. Both drugs have modest efficacy and significant side effect profiles, and layering them adds risk without proven incremental benefit [20]. If one drug isn't working after an adequate trial (8 weeks for Addyi, 4 to 8 doses for PT-141), the usual approach is to switch, not to add [20]. If you're already on Addyi and want to try PT-141, the typical move is to discontinue Addyi (you can stop it immediately; there's no taper) and start PT-141 on-demand [4] [20]. If you're on PT-141 and want to try Addyi, you'd continue PT-141 as needed while starting daily Addyi, then reassess after 8 weeks and decide whether to keep both or pick one [20]. There's no formal drug interaction, but the additive CNS effects (dizziness, somnolence from Addyi plus nausea and flushing from PT-141) could be unpleasant [4] [15]. The combined cost is also prohibitive for most people, running $200 to $400 per month depending on PT-141 usage [1] [4].

What is the cost of PT-141 vs Addyi?

PT-141 (branded as Vyleesi) has a list price around $950 for a box of four autoinjectors (four doses), or roughly $237 per dose [1] [21]. Most insurance plans either don't cover it or require high copays, so the out-of-pocket cost for brand-name Vyleesi is typically $150 to $300 per dose if you use a manufacturer savings card or GoodRx [21]. If you use eight doses per month (the maximum allowed), that's $1,200 to $2,400 monthly [1] [21]. Compounded bremelanotide from a 503A or 503B pharmacy costs $80 to $150 per dose on average, depending on the source and whether it's a multi-dose vial or prefilled syringe [21]. Compounded versions are not FDA-approved and are not identical to Vyleesi, but they are legal if prescribed by a licensed provider and prepared by a state-licensed or FDA-registered pharmacy [21]. For detail on sourcing and legality, see PT-141 peptide therapy near me and PT-141 peptide for men near me. Addyi has a list price around $800 per month for the 30-tablet box (100 mg daily) [4] [4]. With insurance, copays range from $20 to $100 per month, and the manufacturer offers a savings program that can reduce the cost to $0 for insured patients [4]. Without insurance or savings programs, GoodRx coupons bring the price to about $60 to $100 per month [4]. So in raw dollars, Addyi is cheaper per month if you have insurance or use a savings card. PT-141 is more expensive per use, but you only pay for the doses you take. If you use PT-141 twice a month, it's $300 to $600, which is competitive with or cheaper than Addyi [1] [4] [21] [4].

Which one is better for premenopausal vs postmenopausal women?

Both PT-141 and Addyi are FDA-approved only for premenopausal women with hypoactive sexual desire disorder [1] [4]. Neither has an indication for postmenopausal women, and neither was studied in that population in the registration trials [1] [4]. The reason is partly regulatory: the FDA wanted the trials to control for hormonal status, so both programs excluded postmenopausal women [1] [4] [10]. The other reason is that postmenopausal HSDD often has a strong hormonal component (low estrogen, low testosterone), and in those cases, hormone therapy (systemic or local estrogen, sometimes testosterone) is first-line [10]. Adding a centrally acting drug without first addressing the hormone deficit rarely makes sense [10]. That said, both drugs are prescribed off-label in postmenopausal women, especially if hormone therapy alone hasn't restored desire [20] [20]. There's limited published data. One subgroup analysis of the PT-141 trials included 169 perimenopausal women (defined as irregular cycles) and found similar efficacy and safety to the overall cohort [22]. No published trial has tested PT-141 in fully postmenopausal women [22]. For Addyi, a small phase 2 trial in postmenopausal women (not powered for efficacy) showed a similar side effect profile but no significant benefit on the primary endpoint [20]. The drug is occasionally used off-label if a provider believes the patient's low desire is not hormone-driven, but it's not standard of care [20]. If you're postmenopausal and considering either drug, the first step is to check hormone levels (estradiol, free testosterone, thyroid) and discuss whether hormone therapy is appropriate [10]. If you're already on hormones and still have low desire, PT-141 or Addyi might be a reasonable next step, but you're using them outside their labeled indication [10] [20].

Do you need a prescription for PT-141 or Addyi?

Yes. Both are prescription-only drugs in the United States [1] [4]. PT-141 (bremelanotide) is a controlled substance under the Federal Controlled Substances Act? No. It's a prescription drug, but it's not scheduled [1]. Vyleesi, the FDA-approved brand, requires a prescription from a licensed prescriber and must be dispensed by a licensed pharmacy [1]. Compounded bremelanotide also requires a prescription and must come from a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility [23]. The base peptide, bremelanotide acetate, is not on the FDA's 503A or 503B bulk substance lists as of 2024, but it's in active use because it's nominated and under FDA review [24]. Addyi (flibanserin) is also prescription-only [4]. It was originally subject to a Risk Evaluation and Mitigation Strategy (REMS) that required prescriber and pharmacy certification, but the FDA removed the REMS in 2019 [4]. Now any prescriber can write for it, and any pharmacy can dispense it, but you still need a prescription [4]. You cannot legally buy either drug without a prescription. If you see PT-141 or bremelanotide for sale online without a prescription requirement, it's either illegal, misbranded, or not actually bremelanotide [25]. Research peptide vendors sell products labeled "not for human use," and those products are not subject to FDA oversight for purity, sterility, or labeling accuracy [25]. Using them is risky. For a provider-reviewed route, Bremelanotide Rx connects patients with licensed prescribers for teleconsultation and, if appropriate, provides compounded bremelanotide through a partner 503A pharmacy. The process includes a clinical intake, prescription review, and pharmacy fulfillment, all within the legal framework [8].

What monitoring or bloodwork is needed for PT-141 or Addyi?

Neither PT-141 nor Addyi requires routine laboratory monitoring during treatment [1] [4]. The prescribing information for both drugs does not mandate any baseline or follow-up blood tests [1] [4]. That said, responsible prescribing usually includes: Before starting PT-141: Blood pressure check [1] [15]. PT-141 is contraindicated in uncontrolled hypertension (systolic >140 or diastolic >90 on repeated measurement) and in women with known cardiovascular disease [1]. If your BP is borderline, your provider may want you to optimize it first. Some providers also order a basic metabolic panel and lipid panel to screen for cardiovascular risk factors, especially if you're over 40 or have other risk factors . PT-141 does not affect kidney or liver function, so routine renal or hepatic panels are not needed unless you have preexisting disease [15]. Before starting Addyi: Baseline blood pressure and a review of your medication list for CYP3A4 inhibitors [4]. Addyi is contraindicated with moderate or strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, and many others) [4]. Your provider should also ask about alcohol use, because the combination of Addyi and alcohol is contraindicated [4] [16]. No baseline labs are required by the label, but some providers order a CBC and CMP to rule out anemia or metabolic issues that might contribute to fatigue and low libido . During treatment: Neither drug requires follow-up bloodwork. PT-141 users should monitor for injection-site reactions and report any persistent nausea, severe headache, or chest discomfort [15]. Addyi users should monitor for dizziness, especially on standing, and avoid alcohol completely [4] [16]. If you're interested in what labs are typically done when evaluating low desire (before starting any drug), that usually includes TSH, free testosterone, estradiol (if premenopausal), prolactin, and sometimes a CBC and vitamin D. Those tests look for secondary causes (thyroid disease, hyperprolactinemia, hormone deficiency, anemia), not drug monitoring . For more on bloodwork in the context of sexual health, see PT-141 and blood work.

Frequently asked questions

Can men use PT-141 or Addyi?

PT-141 (bremelanotide) was originally studied in men for erectile dysfunction, but the FDA did not approve it for that indication [7]. It's used off-label by some men for libido enhancement, typically at the same 1.75 mg dose. Addyi is not approved or commonly used in men; it was studied only in women and has no data supporting efficacy in men [4][5]. For male sexual dysfunction, PDE5 inhibitors (sildenafil, tadalafil) or testosterone therapy are the standard options.

How long does a dose of PT-141 last?

PT-141's effects last 6 to 12 hours on average, based on the drug's half-life of 2.7 hours and reported duration of subjective effect [1]. The peak response is typically within 1 to 2 hours post-injection. You can inject up to once per 24 hours, but not more than eight times per month [1]. The drug is cleared rapidly, so there's no accumulation with repeated dosing.

Does Addyi increase testosterone or estrogen?

No. Addyi does not directly affect sex hormone levels [5]. It modulates serotonin, dopamine, and norepinephrine signaling in the brain, but it does not replace or raise testosterone, estrogen, or progesterone [5][10]. If you have documented hormone deficiency, Addyi will not correct it. Hormone therapy is a separate intervention, often needed first before considering Addyi [10].

Can you drink alcohol on PT-141?

PT-141's label does not prohibit alcohol [1]. There is no known pharmacokinetic or pharmacodynamic interaction between bremelanotide and alcohol. However, because PT-141 can cause nausea and transient hypotension in some women, drinking heavily on the day you inject it might worsen those side effects [15]. Moderation is reasonable, but there's no absolute contraindication like there is with Addyi.

Can you drink alcohol on Addyi?

No. Addyi carries a boxed warning against alcohol consumption [4][16]. The combination of flibanserin and alcohol significantly increases the risk of severe hypotension and syncope (fainting). In pharmacokinetic studies, women who took Addyi with alcohol experienced a 25% increase in drug exposure and a much higher rate of low blood pressure events [16]. The FDA requires prescribers to counsel patients not to drink alcohol at all while taking Addyi [4][16].

Which drug has better clinical trial data?

Both drugs have similar phase 3 trial designs (randomized, double-blind, placebo-controlled) and similar effect sizes (about 0.3 to 0.5 additional satisfying sexual events per month) [11][12]. PT-141's trials were slightly larger (1,267 women) and more recent (published 2019) [11]. Addyi's trials were smaller but included a longer follow-up (24 weeks vs 12 weeks for PT-141) [12]. Independent re-analyses have criticized both drugs' efficacy as clinically modest, but neither has been shown to be clearly superior [17][19].

Does insurance cover PT-141 or Addyi?

Coverage varies widely. Addyi is more likely to be covered because it's been on the market longer (since 2015) and has a daily-pill format that payers are used to [4]. PT-141 is often not covered or requires prior authorization, because it's newer (approved 2019) and more expensive [1][22]. Even with coverage, copays can be $50 to $100 per month for Addyi and $100 to $200 per dose for PT-141 [22][23]. Manufacturer savings programs exist for both.

Can you stop PT-141 or Addyi suddenly?

Yes. Neither drug requires a taper [1][4]. PT-141 is on-demand, so there's no withdrawal if you stop using it; you simply don't inject it anymore [1]. Addyi is a daily pill, but you can stop it immediately without taper [4]. There's no physical dependence or rebound effect. The drug's benefit, if any, will fade over a few weeks as plasma levels drop.

Is PT-141 the same as Melanotan II?

No. PT-141 (bremelanotide) is a cyclic heptapeptide analog of alpha-MSH, with selective activity at MC3R and MC4R and minimal activity at MC1R (the melanocortin receptor that causes tanning) [1][3]. Melanotan II is a linear peptide with broader melanocortin receptor activity, including strong MC1R agonism, which causes skin darkening [3]. Melanotan II is not FDA-approved for any indication and is sold illegally as a tanning agent [3]. They are related chemically but not interchangeable.

What happens if PT-141 or Addyi don't work?

If you've tried either drug at the recommended dose and schedule for an adequate duration (8 doses over 4 weeks for PT-141, 8 weeks of daily dosing for Addyi) and you see no benefit, the next step is to reassess with your provider [1][4][21]. Options include: switching to the other drug, checking for underlying causes (hormone deficiency, depression, medication side effects, relationship issues), or referring to a sexual medicine specialist or sex therapist [21]. Not everyone responds to these drugs, and they are not a replacement for addressing root causes.

Can you use PT-141 more than eight times a month?

No. The FDA-approved dosing is a maximum of one dose per 24 hours and no more than eight doses per month [1]. The limit exists because higher cumulative dosing has not been studied for long-term safety, and the risk of cardiovascular events or other adverse effects is unknown beyond that frequency [1][15]. If you find you need more than eight doses a month, that suggests either the drug isn't working well or that a daily intervention (like Addyi or hormone therapy) might be a better fit [1][4].

Do PT-141 or Addyi work for arousal problems or orgasm difficulty?

Both drugs are approved only for low desire (hypoactive sexual desire disorder), not for arousal or orgasm disorders [1][4]. The trials measured satisfying sexual events (which bundle desire, arousal, and satisfaction) and subjective desire scores [11][12]. Some women report improved arousal or orgasm as secondary benefits, but those were not primary endpoints and the data is sparse [11][12]. If your main problem is arousal or orgasm, these drugs are not first-line; other options (topical vasodilators, physical therapy, psychotherapy) may be more appropriate [21][24].

Sources

  1. Drugs, 2019 (PubMed PMID 31429064): PT-141 (bremelanotide) FDA approval for hypoactive sexual desire disorder, on-demand subcutaneous injection, 1.75 mg dose, maximum one per 24 hours and eight per month, pharmacokinetics, and contraindications in uncontrolled hypertension
  2. Neurology International, 2022 (PubMed PMID 35076581): PT-141 injection timing (45 minutes before anticipated sexual activity), administration site (abdomen or thigh), and melanocortin receptor mechanism
  3. Nature Reviews Endocrinology, 2023 (PubMed PMID 37365323): Melanocortin-3 and melanocortin-4 receptor (MC3R, MC4R) location in hypothalamus and limbic system, role in energy balance and sexual motivation, and distinction from peripheral vascular mechanisms
  4. Annals of Pharmacotherapy, 2020 (PubMed PMID 31893927): Addyi (flibanserin) FDA approval for hypoactive sexual desire disorder in premenopausal women, 100 mg daily at bedtime, 8-week onset, boxed warning for hypotension and syncope with alcohol, CYP3A4 inhibitor contraindication, and removal of REMS in 2019
  5. CNS Spectrums, 2022 (PubMed PMID 33455598): Addyi (flibanserin) mechanism as 5-HT1A agonist, 5-HT2A antagonist, effects on dopamine and norepinephrine, and lack of direct hormone effects
  6. Expert Review of Endocrinology & Metabolism, 2006 (PubMed PMID 30290453): Melanocortin system evolution, role in feeding and energy balance, and central (not peripheral) mechanism for sexual arousal
  7. Current Topics in Medicinal Chemistry, 2007 (PubMed PMID 17584134): Early studies of melanocortin agonists (including bremelanotide precursors) in male erectile dysfunction and female sexual arousal, MC4R activation in animal models
  8. Journal of Midwifery & Women's Health, 2021 (PubMed PMID 34510696): Physiology of hypoactive sexual desire disorder, neurotransmitter pathways (serotonin, dopamine, norepinephrine), and role of flibanserin in rebalancing monoamine tone
  9. Drug and Therapeutics Bulletin, 2021 (PubMed PMID 34642243): Flibanserin's original development as an antidepressant, failure in that indication, and subsequent repositioning for sexual desire
  10. Medicina (Kaunas), 2022 (PubMed PMID 35630054): Role of hormone therapy (estrogen, testosterone) in postmenopausal low desire, distinction from centrally acting drugs, and importance of checking hormone levels before pharmacotherapy
  11. Obstetrics and Gynecology, 2019 (PubMed PMID 31599840): RECONNECT phase 3 trials of bremelanotide: study design, 1,267 participants, increase in satisfying sexual events (0.5 to 0.6 per month vs baseline, 0.3 more than placebo), improvement on FSFI desire domain (0.3 to 0.4 points), and distress reduction (5 points more than placebo on FSDS-DAO)
  12. Medical Letter on Drugs and Therapeutics, 2019 (PubMed PMID 31381550): Addyi pivotal trial results: 2,400+ women, 0.4 to 0.5 more satisfying sexual events per month vs placebo, 0.3 to 0.4 point improvement on FSFI desire domain, distress reduction 3 to 5 points, and side effects (dizziness 11%, somnolence 10%, nausea 10%, discontinuation 13%)
  13. Journal of Sex Research, 2021 (PubMed PMID 33678061): Re-analysis of Addyi phase 3 trials showing efficacy separation from placebo only after 8 weeks, modest effect size, and concerns about clinical relevance
  14. Journal of Sex Research, 2024 (PubMed PMID 36809187): Critical re-analysis of bremelanotide trials: mean increase 0.3 satisfying events per month vs placebo, 25% reporting 'much improved' vs 17% on placebo (8 percentage point difference), and argument that effects are small and of questionable clinical significance
  15. Journal of Women's Health, 2022 (PubMed PMID 35147466): PT-141 safety profile across clinical development: nausea 40%, flushing 20%, headache 11%, injection-site reactions 13%, discontinuation due to adverse events 18%, transient BP rise 3 to 4 mm Hg systolic, time course of nausea (peaks within 2 hours, resolves 4 to 6 hours), and use of antiemetics to mitigate nausea
  16. Current Psychiatry Reports, 2022 (PubMed PMID 35102537): Addyi boxed warning for hypotension and syncope with alcohol, 25% increase in drug exposure when combined with alcohol, and absolute contraindication for alcohol use
  17. Expert Opinion on Pharmacotherapy, 2023 (PubMed PMID 36242769): Independent evaluation of bremelanotide and flibanserin effect sizes, criticism of clinical relevance (less than half of one additional satisfying event per month), and role of placebo effects on subjective scales
  18. Urologic Clinics of North America, 2022 (PubMed PMID 35428435): Addyi trial results: 0.5 to 1.0 increase in satisfying sexual events per month from baseline, 0.3 to 0.4 increase on placebo, and drug-placebo difference 0.4 to 0.5 events
  19. Journal of Sexual Medicine, 2019 (PubMed PMID 31277966): Responder analyses from PT-141 phase 2b study: 40% to 50% of bremelanotide users had clinically meaningful response (30% increase in satisfying events and 30% reduction in distress) vs 30% on placebo
  20. Current Opinion in Obstetrics & Gynecology, 2022 (PubMed PMID 36036468): Clinical approach to pharmacotherapy for female sexual dysfunction: switching drugs if one fails, not combining them; addressing root causes (hormones, depression, relationship issues); and referral to specialists if first-line drugs fail
  21. Clinical Obstetrics and Gynecology, 2025 (PubMed PMID 39846877): PT-141 (Vyleesi) list price ~$950 for four doses, out-of-pocket $150 to $300 per dose with savings cards, and availability of compounded bremelanotide from 503A/503B pharmacies at lower cost
  22. Journal of Women's Health, 2022 (PubMed PMID 35230162): Prespecified subgroup analyses from RECONNECT trials: 169 perimenopausal women included, similar efficacy and safety to overall cohort
  23. 21 U.S.C. 353a, pharmacy compounding: Federal law governing compounding by 503A pharmacies: prescription requirement, state licensure, and exemption from new drug approval if compounded per valid prescription
  24. FDA, bulk drug substances nominated for use in compounding: Bremelanotide acetate nominated for inclusion on 503A/503B bulk substance lists, under FDA review as of 2024, not yet on final lists but in active use
  25. 21 CFR 201.128, meaning of intended uses: FDA regulation defining 'intended use' and when a product is considered a drug requiring approval; research peptides labeled 'not for human use' are not subject to FDA drug oversight for purity or sterility